Abstract

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.
Takafumi Tsushima ... Kentaro Narita
British journal of haematology | VOL. 193
Takafumi Tsushima, et. al.Takafumi Tsushima ... Kentaro Narita
21 Mar 2021
Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study
Despina Fotiou ... Marie-Christine Kyrtsonis
Blood | VOL. 138
Despina Fotiou, et. al.Despina Fotiou ... Marie-Christine Kyrtsonis
05 Nov 2021
The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment
Zhen-Yu Li ... Ling-Ling Yin
Zhongguo shi yan xue ye xue za zhi | VOL. 31
Zhen-Yu Li, et. al.Zhen-Yu Li ... Ling-Ling Yin
01 Feb 2023
Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy
...
Chinese Journal of Hematology | VOL. 34
, et. al. ...
01 Apr 2013
View more papers

More From: American journal of hematology

Paper Title
Journal
Date
Author
A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
Richard Allen ... Huzefa Bahrain
American journal of hematology | VOL. 99
Richard Allen, et. al.Richard Allen ... Huzefa Bahrain
01 Jun 2024
-
-
American Journal of Hematology | VOL. 99
--
01 Jun 2024
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Tamer Othman ... Matthew Mei
American journal of hematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Matthew Mei
28 May 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Tamer Othman ... Paul Koller
American journal of hematology | VOL. -
Tamer Othman, et. al.Tamer Othman ... Paul Koller
27 May 2024
View more papers